Research and Markets: PharmaPoint: Seasonal Influenza Vaccines - France Drug Forecast and Market Analysis

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/z8k68j/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis" to their offering.

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will stealmarket share, patient share, and revenue from the trivalent influenza vaccines currently available.

The French influenza vaccine market is valued at approximately $47.8 million in 2012. The projected drivers of sales growth include the growth of the elderly population and introduction of quadrivalent seasonal influenza vaccines. Sanofi is the market leader in France. The French influenza manufacturer controls over a third of the influenza vaccine market in this country, with a portfolio that includes trivalent intramuscular influenza vaccines Vaxigrip and Mutagrip and an intradermal vaccine, Intanza. Sanofi's home field advantage and novel products have enabled it to dominate the French market.

Scope

Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in France from 2012 to 2022.
Analysis of the impact of key events as well the drivers and restraints affecting the France seasonal influenza market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012 to 2022 in France.

Product Profiles - Major Brands

- Fluarix/FluLaval

- Vaxigrip/Mutagrip

- Influvac

- Fluad

- Fluzone ID (Intradermal)

- Optaflu

For more information visit http://www.researchandmarkets.com/research/z8k68j/pharmapoint

Source (News - Alert): GlobalData